Tag: partnerships

BEIJING, June 12, 2025 (GLOBE NEWSWIRE) -- The “International Editors-in-Chief Roundtable,” co-hosted by Global Times and Global Times Online (huanqiu.com), was recently held, bringing together editors-in-chief from China, Latin America, and around the world. Centered on the theme of "Harmony and Integration" Approach to China–Latin America Civilizational Exchange, the forum called for enhanced cross-cultural dialogue and practical cooperation to jointly build a more balanced and inclusive international media landscape.

Manila, 12 June (Globe Newswire) –  iGaming.com officially announced the publication of its updated rankings to licensed online casinos in the Philippines for 2025, providing Filipino players with new insights into regulated operators, secure platforms, and responsible gaming resources. This newly released report reflects the latest market developments and regulatory updates affecting the Philippine iGaming sector. 

The 2025 report on Autoimmune Collaboration & Licensing Deals analyzes 943 agreements from 2016-2025, covering over 30 diseases including MS, RA, lupus, and Crohn’s. Access deal terms, financials, and SEC contracts for top biopharma partnerships. A must-have for benchmarking, due diligence, and strategic planning in autoimmune R&D and commercialization.

BRUSSELS and CAMBRIDGE, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ: BIIB) today presented additional detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP), a novel Fc-free anti-CD40L drug candidate. In the study, DZP demonstrated significant clinical improvements in disease activity in people living with moderate-to-severe systemic lupus erythematosus (SLE), as measured by the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) at Week 48, the primary endpoint. Improvements were also seen across additional clinical measures, including fatigue and disease activity/remission. These results were presented at EULAR 2025, the European Alliance of Associations for Rheumatology’s annual meeting, in Barcelona, Spain. The safety and efficacy of DZP in SLE have not been established, and it is not approved for use in SLE by any regulatory authority worldwide. A second Phase 3 trial of dapirolizumab pegol is ongoing with the goal of confirming the results from PHOENYCS GO.